Research output per year
Research output per year
Fingerprint
Dive into the research topics where Willem Witlox is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Research output
-
Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective
Sugden, B. M., Grimm, S. E., Wolff, R., Armstrong, N., Otten, T., Abu-Zahra, T., Perry, M., Patel, M., Chen, J., Noake, C., Joore, M. & Witlox, W. J. A., 1 May 2024, In: Pharmacoeconomics. 42, 6, p. 615-618 4 p.Research output: Contribution to journal › Article › Academic › peer-review
Open Access -
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Wijnen, B., Witlox, W., Wolff, R., Fayter, D., Ramaekers, B., Otten, T., Ryder, S., Posadzki, P., Worthy, G., Stirk, L., Armstrong, N., Kleijnen, J. & Joore, M., Jan 2023, In: Pharmacoeconomics. 41, 1, p. 33-42 10 p.Research output: Contribution to journal › (Systematic) Review article › peer-review
Open Access -
Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Witlox, W., Grimm, S., Howick, J., Armstrong, N., Ahmadu, C., McDermott, K., Otten, T., Noake, C., Wolff, R. & Joore, M., Aug 2023, In: Pharmacoeconomics. 41, 8, p. 857-867 11 p.Research output: Contribution to journal › (Systematic) Review article › peer-review
Open Access -
Risk factors for cognitive impairment in radically treated stage III NSCLC : Secondary findings of the NVALT-11 study
Zeng, H. Y., Hendriks, L. E. L., Witlox, W. J. A., Groen, H. J. M., Dingemans, A. M. C., Praag, J., Belderbos, J., Houben, R., van der Noort, V. & De Ruysscher, D. K. M., 1 Jun 2023, In: Radiotherapy and Oncology. 183, 1, 10 p., 109627.Research output: Contribution to journal › Article › Academic › peer-review
Open Access -
Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Grimm, S. E., Witlox, W., Wolff, R., Chalker, A., Hiligsmann, M., Wijnen, B., Ahmadu, C., Ryder, S., Armstrong, N., Duffy, S., Syndikus, I., Kleijnen, J. & Joore, M. A., May 2022, In: Pharmacoeconomics. 40, 5, p. 575-575 1 p.Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic
Open Access